Lead Product(s): Antibody drug conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Novo Seeds
Deal Size: $62.2 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 29, 2021
The new financing, which is the largest Series A financing for a Danish biotech company, will be used to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting the novel cancer target uPARAP/Endo180 to proof of concept in patients.